In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commiss
Illumina has said it will divest cancer detection company Grail, marking the end of a long-running antitrust dispute that has claimed the jobs of its former CEO and chair.
The European Commission has levied a substantial penalty on DNA sequencing giant Illumina for closing its takeover of cancer detection company Grail without EU regulatory
Researchers in the UK say Grail’s blood test for more than 50 different types of cancer has shown promise in a trial involving thousands of people with suspected cancer sy
Illumina shareholders have voted to oust the company’s chairman John Thompson, although chief executive Francis DeSouza has emerged from the annual meeting unscathed.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS